Kornimate/medical-research-clean huggingface dataset:
chemoradiotherapy in stage iii non-small cell lung cancer (nsclc)

Conditions: Stage III Non-small Cell Lung Cancer

Summary: radiochemotherapy is a standard for the treatment of unresectable stage iii non-small cell lung cancer. the investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.


Eligibility criteria:
inclusion criteria: * non-squamous stage iii non-small cell lung cancer * measurable disease (recist 1.1) * ecog performance status 0-1 * normal organ and marrow function exclusion criteria: * prior chest radiation therapy * history of any cancer other than nsclc (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years. * prior therapy with known specific inhibitors of the egfr. * history of severe allergic reaction to prior therapy with monoclonal antibodies
gemcitabine, oxaliplatin in combination with bevacizumab in biliary tract and gallbladder cancer

Conditions: Biliary Tract Cancer; Gallbladder Adenocarcinoma

Summary: the purposes of this study are to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good and bad) this combination has on patients with cancer of bile duct or gallbladder. bevacizumab has been shown to slow or stop cell growth in tumors by decreasing the blood supply to the tumors.

* the chemotherapy drugs are given twice every 28 days. this 28 day period is called a cycle of study treatment. * bevacizumab will be administered by iv over 90 minutes on day 1 and day 15. gemcitabine will be administered by iv over 1 hour and 40 minutes on days 1 and 15 of each cycle. oxaliplatin will be administered by iv for 2 hours on days 1 and 15 of each cycle. * the following tests and procedures will be performed on day 1 and day 15 or each cycle: physical examination; medical history; blood work; and urine test. a pet scan will be repeated at the end of cycle 2 and ct scans will be repeated once every 8 weeks. * participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects.

Eligibility criteria:
inclusion criteria: * histologically confirmed, locally unresectable or metastatic biliary tract or gallbladder adenocarcinoma. patients must have at least one measurable lesion outside prior radiation field. * zero to one prior chemotherapy for biliary tract or gallbladder cancer * age \> 18 years * ecog performance status 0-2 * life expectancy \> 12 weeks * adequate organ and bone marrow function exclusion criteria: * chemotherapy within past 3 weeks of initiation of therapy * pregnant or lactating women * clinically apparent central nervous system metastases or carcinomatous meningitis * biliary obstruction with inadequate drainage and total bilirubin \> 2.5 mg/dl * concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * uncontrolled serious medical or psychiatric illness * pre-existing peripheral neuropathy of grade 2 or greater severity according to the common terminology criteria of the nci (version 3.0) * current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study * blood pressure of \> 150/100 mmhg * unstable angina * nyha grade ii or greater congestive heart failure * history of myocardial infarction or stroke within 6 months * clinically significant peripheral vascular disease * evidence of bleeding diathesis or coagulopathy * major surgical procedure, open biopsy, or significant traumatic injury with 28 days prior to day 1, anticipation of need for major surgical procedure during the course of the study * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 1 * serious, non-healing wound, ulcer, or bone fracture

Keywords: avastin gemox
effect of low power laser in the pain after lower tooth extraction

Conditions: Third Molar Extraction; Oral Pain; Tooth Extraction

Summary: introduction: previously published studies report a prevalence ranging from 35.9% to 58.7% of the general population with at least one impacted wisdom tooth. surgical extraction of wisdom teeth is the procedure most often associated with postoperative complications, such as pain, swelling, trismus, and oral discomfort during the first postoperative days. these complications arise from an inflammatory response, which is a direct and immediate consequence of the surgical intervention and can limit the patients' daily functions in the recovery phase and compromise their quality of life. several methods have been used to control postoperative morbidity related to wisdom tooth extraction, including administration of proteolytic enzymes, tube drains, cryotherapy, anti-inflammatory and analgesic drugs and low level laser therapy. objectives: to test whether the use of low power laser can improve post-operative pain, swelling and healing of the surgical wound. material and methods: a double-centre, randomised, split-mouth, double-centre clinical study will be carried out in 38 patients per centre, totalling 76 patients and 152 wisdom teeth, who will undergo surgery for the extraction of the lower third molars. the necessary data for the study will be taken on the days of the consultation for surgery planning, on the day of surgery, by the patient on each post-operative day and on the 7th post-operative day (at the time of suture removal ).


Eligibility criteria:
inclusion criteria: * patients who require extraction of the two lower wisdom teeth due to previous infection or pain, orthodontics or crowding, caries and who have a similar degree of difficulty according to the pell and gregory/winter classifications. * patients must have the capacity to understand and decide at the time of voluntarily signing the informed consent before any intervention related to the study is performed. * patients who, after being informed about the aims and procedures of the research, agree and sign the informed consent form. patients must be willing and able to adhere to the study in order to complete the necessary visits. exclusion criteria: * patients with uncontrolled systemic disease (asa ≥ iii). * patients with severe periodontal disease or acute pericoronitis. * smokers of more than 5 cigarettes per day. * pregnant and lactating women, as the effect of laser therapy in this population has not been studied, its use is contraindicated.

Keywords: dentistry tooth extraction photobiomodulation pain
study of anti-epidermal growth factor receptor (egfr) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with stage iv lung cancer

Conditions: Stage IV Non-Small Cell Lung Cancer

Summary: the objective is to evaluate the toxicity profile, response rate, and time to progression of cetuximab administered in combination with either carboplatin + gemcitabine in patients with advanced non-small cell lung cancer with positive egfr expression.

the primary objective of this study is to evaluate the safety profile of cetuximab when used in combination with gemcitabine and carboplatin in patients with egfr positive, chemotherapy-naive, stage iv non-small cell lung cancer (nsclc). also, the study will determine the response rate in patients with egfr positive chemotherapy-naive, stage iv non-small cell lung cancer (nsclc) treated with cetuximab in combination with gemcitabine and carboplatin as well as determine the time to progression in patients with egfr positive chemotherapy-naive, stage iv nsclc treated with cetuximab in combination with gemcitabine and carboplatin.

Eligibility criteria:
inclusion criteria: * have a diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (nsclc). * have uni-dimensionally measurable and/or evaluable advanced nsclc. * have stage iv or recurrent disease following radiation therapy. * have ecog performance status of 0-1 or karnofsky performance status of 80- 100 at study entry. * have given signed informed consent. * be at least 18 years of age. * have anc greater than or equal to 1,500/mm3, platelets greater than or equal to 100,000/mm3, wbc greater than or equal to 3,000 mm3, and hemoglobin greater than or equal to 9 g/dl. * have total bilirubin less than or equal to 1.5 x upper limits of normal, alk phos, ast and alt less than or equal to 2.5 x upper limits of normal. * have serum creatinine less than or equal to 1.5 mg/dl, or calculated creatinine clearance greater than or equal to 60 cc/minute. * be disease free from a previously treated malignancy for more than three years. patients with a history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded. * agree to use effective contraception if procreative potential exists. * must have positive egfr expression (tumor tissue) by immunohistochemical assay. exclusion criteria: * have received prior murine monoclonal antibody or cetuximab therapy. * have disease amenable to curative surgery. * have received prior chemotherapy. * have received radiation therapy within 3 weeks prior to the first infusion of cetuximab. * have a history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities, in the judgment of the pi. * have uncontrolled seizure disorder, active neurological disease, or grade 2 or higher neuropathy. * be pregnant or breast-feeding. * have received any investigational agent(s) within 1 month of study entry.

Keywords: egfr cetuximab gemcitabine carboplatin nsclc
standardized fecal microbiota transplantation for crohn's diseases

Conditions: Inflammatory Bowel Disease; Crohn&#39;s Disease (CD)

Summary: the gut microbiota is considered to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body's metabolism. evidence from animal and human studies strongly supports the link between intestinal bacteria and inflammatory bowel diseases (ibd). dozens of studies reported its efficacy in treatment of severe clostridium difficile colitis. preliminary studies using fecal microbiota transplantation (fmt) for ulcerative colitis (uc), crohn's diseases (cd), irritable bowel syndrome (ibs) and constipation have also met with some success. however, the results on cd is very limited. this marks the initial step in exploring the potential efficacy of fecal bacteriotherapy for cd. the investigators aim to evaluate the effectiveness, durability, and safety of fmt in a cohort of at least 500 patients with cd over a ten-year period

the present clinical trial aims to re-establish a gut functionality state of intestinal flora through fmt as a therapy for cd (all age range,hbi\>4). we established a standard microbiota isolation from donated fresh stool in lab. the microbiota is then transplanted into the intestine via endoscopy or other established methods, such as mid-gut or colonic transendoscopic enteral tubing. patients from multi-clinical centers in this study will be assigned to receive fmt or traditional treatments according to associated guidelines and follow-up for at least one year. blood tests, imaging, endoscopy and questionnaire will be used to assess participants at study start and at study completion.

Eligibility criteria:
inclusion criteria: clinical diagnosis of crohn's disease, with the diagnosis remaining unchanged after at least three months of follow-up. willingness to undergo fmt (fecal microbiota transplantation). exclusion criteria: presence of serious conditions that made them unsuitable for inclusion (e.g., malignant neoplasms, cardiopulmonary failure, serious liver or kidney disease).

Keywords: inflammatory bowel disease fecal transplantation fecal bacteriotherapy fecal microbiota transplantation crohn&amp;#39;s disease
research on innovative diagnosis and treatment system of syndrome differentiation of zang-fu viscera and effectiveness evaluation based on inter-arm blood pressure measured simultaneously

Conditions: Insomnia; Chronic Gastritis

Summary: by combining the measurement of blood pressure in both arms with the information of the four diagnoses of tcm, we try to form a diagnostic model of "five diagnoses combined with ginseng" based on tcm zang-fu syndrome differentiation. it can further objectify and visualize the fuzzy four diagnostic indicators of tcm. in order to solve the problem of data differentiation of tcm four diagnoses, and optimize the five diagnoses of tcm conjunctive index, explore the establishment of tcm intelligent diagnosis and treatment and contact evaluation computer system


Eligibility criteria:
inclusion criteria: case inclusion criteria: * patients were treated with epigastric pain and / or insomnia, which met the above diagnostic criteria for diseases, liver and spleen; * diagnostic criteria for diseases, liver and spleen; * age 18-65 years old; * it can combine mild and moderate depression, anxiety sign the informed consent form. healthy control inclusion criteria: * psqi \< 5 points; * no hypertension, diabetes, hyperlipidemia, coronary heart disease and other underlying diseases; * no depression, anxiety, malignant tumor, syphilis, hiv and other infectious diseases; * over 18 years of age; * volunteer to participate in this study, cooperate with the measurement of blood pressure in both arms, and sign the informed consent. exclusion criteria: case exclusion criteria: * patients with insomnia disorder caused by uneffectively controlled or serious diseases, such as malignant tumor, persistent pain, cardiovascular and cerebrovascular diseases, endocrine diseases, etc.; * patients with severe depression and mental illness; * pregnant and lactation patients. healthy controls exclusion criteria: * sleep apnea syndrome or restless leg syndrome and other sleep disorders; * pregnant and lactation; * abnormal symptoms and abnormal tongue pulse occur in the body, such as facial acne, dysmenorrhea, thick and greasy tongue coating, loose stools, fat tongue, teeth marks and tongue.

Keywords: blood pressure in both arms syndrome differentiation liver-spleen disharmony efficacy evaluation
same-day versus separate-day preoperative consultation for mohs surgery

Conditions: Non-melanoma Skin Cancer; Squamous Cell Carcinoma of Skin; Basal Cell Carcinoma

Summary: the purpose of this study is to determine whether separate- versus same-day preoperative consultation affects time to treatment (start to finish), utilization rate of mohs, rate of case cancellations, cost, and patient satisfaction. the investigators hypothesize that patients with same-day preoperative consultation will have a shorter time between cancer diagnosis and removal but, only when coordination of care is needed, longer time between removal and consultation with other specialists, as compared to patients with separate-day consultation. the investigators anticipate that patients with same-day preoperative consultation will have a decrease in travel cost as compared to patients with separate-day consultation. the investigators expect that there will be no difference in various satisfaction matters between groups, with the exception of potentially greater convenience reported by patients in the same-day preoperative consultation group. finally, the investigators hypothesize that there will be no difference between groups in regards to rates of surgery cancellation.

procedure: prospective trial which randomly assigns patients to either separate- or same-day preoperative consultation for mohs surgery. a phone consultation will take place, which will assist in determining whether the patient is appropriate for enrollment into the study. if so, the patient will be randomized to either separate-day or same-day preoperative consultation. materials: patient survey methods of data collection: the patient-specific data obtained from the medical record will include: patient age, number of previous skin cancers, preoperative size, history of cutaneous surgery, employment status, and distance between home address and dermatology facility. outcome measures that will be obtained from the medical record will include: time between cancer diagnosis, removal and defect repair, rate of proceeding with mohs as opposed to other treatment options, and rate of cancelling surgery (due to site discrepancy, anticoagulation issues). a survey will be used to assess patient satisfaction.

Eligibility criteria:
inclusion criteria: * patients will be considered for enrollment if they have been referred to a mohs surgeon for consideration of mohs surgery for non-melanoma skin cancer exclusion criteria: * patients would be excluded if there is a lack of indication for mohs * significant comorbidities, or * in the case of a high-risk location or tumor size, for which in advance it is known that they will need consultation with other specialties

Keywords: mohs surgery preoperative consultation
tumor-microenvironment spatial interaction to identify markers of resistance to therapy in her2+ breast cancer patients

Conditions: HER2-positive Breast Cancer

Summary: this retrospective observational study aims at the comparison of the tumour-microenvironment tissue architecture before and after neo-adjuvant therapy in samples from her2-positive (her2+) breast cancer (brca) patients that display residual invasive disease in the breast/lymph node at surgery after standard-of-care combined chemotherapy and trastuzumab treatment. the working hypothesis of the investigators is that: therapy imposes a selective pressure on tumour-microenvironment features promoting resistance to treatment. participant that have already undergone neo-adjuvant treatment as part of their regular medical care for her2-positive breast cancer will provide access to formalin-fixed paraffin-embedded (ffpe) samples taken before and after therapy. tumoral, peri-tumoral and stromal regions of each specimen will be analyzed with the ultimate goal to identify new biomarkers (and putative targets) of resistance to therapy.


Eligibility criteria:
inclusion criteria: 1. participant is willing and able to give informed consent for participation in the study. 2. patient underwent the following procedure before surgery: biopsy, sequential chemotherapy comprising treatment with antracyclines (ac/ec q21, 4 cycles) followed by taxanes (paclitaxel 1,8,15 q21 for 12 weeks) in combination with the anti-her2 antibody trastuzumab. 3. specimen collected at surgery display residual invasive disease in the breast/lymph node. exclusion criteria: 1. pre-existing conditions or concurrent diagnoses; 2. concomitant use of other medications during neo-adjuvant treatment; 3. quality of stored specimen does not meet the standard for imaging mass cytometry analysis.
irinotecan in treating patients with metastatic or recurrent breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer.

objectives: i. determine the objective response rate to irinotecan in patients with metastatic breast cancer who have received prior anthracycline and taxane based chemotherapy for metastatic disease. ii. determine the toxicities of irinotecan in these patients. iii. determine survival time, duration of response, and time to treatment failure in these patients after this therapy. outline: patients receive irinotecan iv over 90 minutes weekly for 4 weeks. treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. patients are followed at day 30, then every 3 months. projected accrual: a total of 14-29 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven advanced breast cancer must have received anthracycline and taxane based chemotherapy for metastatic disease measurable disease no cns metastases or carcinomatous meningitis hormone receptor status: not specified patient characteristics: age: 18 and over menopausal status: not specified performance status: ecog 0-2 life expectancy: at least 12 weeks hematopoietic: granulocyte count greater than 1500/mm3 hemoglobin at least 9.0 g/dl platelet count greater than 100,000/mm3 hepatic: bilirubin no greater than 1.3 mg/dl sgot no greater than 3 times upper limit of normal (no greater than 5 times uln if liver involvement) no gilbert's disease renal: creatinine no greater than 2.0 mg/dl calcium at least 12.0 mg/dl cardiovascular: no myocardial infarction in the past 6 months no congestive heart failure requiring therapy other: no active or uncontrolled infection hiv negative no psychiatric disorder that would preclude study no prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix no history of seizures no uncontrolled diabetes mellitus (random blood sugar at least 200 mg) no other severe disease that would preclude study not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics greater than 4 weeks since prior chemotherapy no prior irinotecan or topotecan endocrine therapy: not specified radiotherapy: greater than 4 weeks since prior radiotherapy no radiotherapy to greater than 30% of bone marrow surgery: not specified other: no concurrent phenytoin, phenobarbitol, or other antiepileptic prophylaxis

Keywords: stage iv breast cancer recurrent breast cancer